Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03940820 |
Title针对实体瘤患者的 ROBO1 特异性 CAR-NK 细胞临床研究 | 阶段
第 1 阶段/第 2 阶段
|
Date Added 2019-05-07 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
ROBO1 CAR-NK 细胞 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03874897 |
Title在实体瘤中靶向 claudin18.2 的嵌合抗原受体 T 细胞。 | 阶段
第 1 阶段
|
Date Added 2019-03-14 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
CAR-CLDN18.2 T-Cells, Chemotherapy, PD-1 Monoclonal Antibody |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06415851 |
TitleChemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab | 阶段
第二阶段
|
Date Added 2024-05-15 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT04262687 |
TitleChemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | 阶段
第二阶段
|
Date Added 2020-02-10 |
地点
法国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab |
标签
MSS/ MMRp
|
| NCT ID NCT04595266 |
Title化疗栓塞（Lifepearls-伊立替康）在结直肠癌和转移性疾病患者中的应用 | 阶段
第二阶段
|
Date Added 2020-10-20 |
地点
西班牙
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
Anti-EGFR or Bevacizumab, FOLFOX regimen, LIVERPEARLS-Irinotecan |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02675946 |
TitleCGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | 阶段
第 1 阶段
|
Date Added 2016-02-05 |
地点
California, United States
Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maryland, United States Massachusetts, United States Nebraska, United States New Jersey, United States North Carolina, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States 台湾 |
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
cetuximab, CGX1321, encorafenib, Pembrolizumab, Keytruda |
标签
MSS/ MMRp
|
| NCT ID NCT03727763 |
Title西妥昔单抗和维莫非尼联合 FOLFIRI 治疗 BRAF V600E 突变的晚期结直肠癌 (IMPROVEMENT) | 阶段
第二阶段
|
Date Added 2018-11-01 |
地点
中国
|
Prior IO Allowed 没有 |
CRC-directed 是 |
Status
招聘
|
药物
cetuximab, Vemurafenib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05291156 |
TitleCAVE-2 GOIM 研究：阿韦鲁单抗加西妥昔单抗联合疗法作为再挑战策略的临床研究 | 阶段
第二阶段
|
Date Added 2022-03-22 |
地点
意大利
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Avelumab, cetuximab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03297606 |
Title加拿大剖析和靶向制剂利用试验（CAPTUR） | 阶段
第二阶段
|
Date Added 2017-09-29 |
地点
加拿大
|
Prior IO Allowed 没有 |
CRC-directed 没有 |
Status
招聘
|
药物
Axitinib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Nivolumab plus Ipilimumab, Olaparib, palbociclib, Sunitinib, Temsirolimus, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05426005 |
TitleCadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer | 阶段
Phase 1, Phase 2
|
Date Added 2022-06-21 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Cadonilimab |
标签
MSI-H/ MMRd
|
